Sunmax Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 364.76 million compared to TWD 252.59 million a year ago. Revenue was TWD 363.59 million compared to TWD 252.39 million a year ago. Net income was TWD 137.32 million compared to TWD 41.62 million a year ago. Basic earnings per share from continuing operations was TWD 2.52 compared to TWD 0.76 a year ago. Diluted earnings per share from continuing operations was TWD 2.52 compared to TWD 0.76 a year ago. Basic earnings per share was TWD 2.52 compared to TWD 0.76 a year ago. Diluted earnings per share was TWD 2.52 compared to TWD 0.76 a year ago.
For the nine months, sales was TWD 1,012.26 million compared to TWD 754.38 million a year ago. Revenue was TWD 1,010.31 million compared to TWD 754.18 million a year ago. Net income was TWD 409.28 million compared to TWD 149.07 million a year ago. Basic earnings per share from continuing operations was TWD 7.51 compared to TWD 2.74 a year ago. Diluted earnings per share from continuing operations was TWD 7.51 compared to TWD 2.73 a year ago. Basic earnings per share was TWD 7.51 compared to TWD 2.74 a year ago. Diluted earnings per share was TWD 7.51 compared to TWD 2.73 a year ago.